Abstract 1871
Background
Much of the work of a busy oncology day unit is undocumented, especially the work involved in phone triage during the working hours of 8am to 6pm. Phone calls from patients, their family doctors, palliative care teams, or from within the Hospital itself seeking advice form the majority of this aspect of the Specialist Oncology Nurse and Staff Nurses’ time. This project was performed to assess the nature of these calls and the broad advice given to the callers so that a dedicated Acute Review Specialist Oncology Nurse Clinic could be developed.
Methods
In conjunction with key oncology nurses and their medical oncologist colleagues a log to capture each answered call was developed. This centred on the date and time of the call, the source, the issue raised, the advice given, if advised to go to the Emergency Room the reason why, and other actions that were necessary. A form was completed per answered call, and collected at the end of the day. Data was recorded on a spreadsheet. All forms were annonymised with regard to patient identifiers. The forms were focused on whether the issue was successfully addressed within the day unit, the Hospital’s emergency room, the community services, or whether solely by the advice given over the telephone.
Results
A sample size of 252 incoming answered calls by the Oncology Nursing Staff to the Nurses’ station was analysed. Just over half these calls (52%) were made by patients/family members. Other calls related to internal questions such as from Interventional Radiology or other diagnostic areas of the Hospital (26%), pharmacies (7%), and family doctors (4%). The other 11% of calls were mainly from wards relating to advice on inpatients or seeking consults. Of the unwell patients calling for advice, near half (48%) were seeking advice on what action to take: stay at home or come to Hospital. 35% of patients were seeking either a new appointment or change in appointment date. The remaining 17% of patients were seeking non-emergency review by the medical oncology team.
Conclusions
This analysis of answered calls highlights the need for involvement of experienced oncology nurses in the triage of phone calls to a busy oncology day unit, and the need to develop an Acute Review Clinic, managed by an experienced oncology nurse specialist.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont Hospital Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract